• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Charging Robotics Inc
Daseke, Inc. - Common Stock
FF EAI Robotics Ecosystem Inc. - Common Stock
MGM Growth Properties LLC Class A common shares representing limited liability c
MGP Ingredients, Inc. - Common Stock
Phillips 66 Partners LP Common Units representing limited partner interest in th
Playa Hotels & Resorts N.V. - Ordinary Shares
Pudo Inc
iOThree Limited - Ordinary Shares
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmadrug Inc (CSE:PHRX)

0.0050 UNCHANGED
Delayed Quote Updated: 9:30 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharmadrug Inc

News headline image
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
May 13, 2026
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a... 
Via Newsfile
News headline image
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
Biotech Veteran David Kideckel Joins the Board of PharmaDrug
August 30, 2021
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
News headline image
PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to Evaluate DMT in a Comparative Clinical Study
August 25, 2021
Toronto, Ontario--(Newsfile Corp. - August 25, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
News headline image
PharmaDrug Announces Appointment of Auditor
August 06, 2021
Toronto, Ontario--(Newsfile Corp. - August 6, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a... 
Via Newsfile
Topics Cannabis
News headline image
PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease
August 05, 2021
Unlocking the potential of psychedelics, including DMT, and other tryptamines to treat the significant unmet medical needs of glaucoma patientsPartnering... 
Via Newsfile
Topics Cannabis Law Enforcement
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap